Which of the following statements correctly pair the immunomodulators with its appropriate mechanism of action?
A. Tacrolimus - increases the catabolism of IgG antibodies B. Azathioprine - stimulates interleukin-2 synthesis in CD4 helper cells C. Sirolimus - inhibits mammalian kinase D. Cyclophosphamide - inhibits inosine monophosphate dehydrogenase E. Muromonab-CD3 - inhibits calcineurin F. Daclizumab - blocks interleukin-2 receptors
Sirolimus - inhibits mammalian kinase-2. daclizumab - blocks interleukin-2 receptors-answer: cf(hardman, pp 1470, koda-kimble, pp 35-8)sirolimus is an antibiotic that, like tacrolimus, binds to a fk-binding protein. the sirolimus-proteincomplex binds to mammalian kinase, an enzyme which is essential for cell-cycle progression, resultingin cell-cycle arrest in the late g1-phase. daclizumab is a monoclonal antibody against the interleukin-2 receptors present on the surface of tcells. the drug prevents the il-2 mediated t cell activation events (e.g. activation of cd4 t helper cells).a) glucocorticoids, not tacrolimus, increase the catabolism of igg antibodies.b) azathioprine is an immunosuppressant drug. stimulation of interleukin-2 synthesis would causeimmunostimulant effects.d) mycophenolate mofetil, not cyclophosphamide, inhibits inosine monophosphate dehydrogenase.e) cyclosporine and tacrolimus, not muromonab-cd3, inhibit calcineurin